Sana: Q3 Earnings Snapshot
Sana Biotechnology, Inc. SANA
$2.37
▼ -3.85%
($-0.10)
🔥 High Short Interest
🎢 High Beta
Open
$2.42
Prev Close
$2.47
Day Range
$2.31 – $2.52
52W Range
$2.22 – $5.49
Market Cap
$738.60M
Beta
2.40
EPS (TTM)
$-0.76
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-02-04 |
| Shares Out. | 299,360,000 |
| Website | sana.com/ ↗ |
| Phone | 12067017914 |
| Employees | 142 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$63.6M |
| Free Cash Flow | -$135.1M |
| Total Assets | $431.5M |
| Total Liabilities | $277.0M |
| Equity | $154.6M |
About Sana Biotechnology, Inc.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates comprises SC291, SC262, UP421, and others.
Sana Biotechnology, Inc. is a publicly traded company under the ticker symbol SANA on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
15 analysts (2026-11-01)